Innate immunity in inflammatory bowel disease: A disease hypothesis

Journal of Pathology

Volumn 214, Issue 2, 2008, Pages 260-266

  Marks, D J B ^a   Segal, A W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Bowel; Crohn's; Cytokine; Macrophage; Neutrophil

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; TOLL LIKE RECEPTOR 2;

ALLELE; CHRONIC GRANULOMATOUS DISEASE; CROHN DISEASE; CYTOKINE PRODUCTION; ENTERITIS; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; GLYCOGEN STORAGE DISEASE; HETEROZYGOSITY; HUMAN; IMMUNE DEFICIENCY; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; CROHN DISEASE; GASTROINTESTINAL AGENTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, NATURAL; NEUTROPHILS; NOD2 SIGNALING ADAPTOR PROTEIN;

EID: 38549087476     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2291     Document Type: Review

References (70)

1. Shanahan F. Crohn's disease. Lancet 2002;359(9300):62-69.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347(6):417-429.
3. Chiodini RJ, Van Kruiningen HJ, Thayer WR, Coutu JA. Spheroplastic phase of mycobacteria isolated from patients with Crohn's disease. J Clin Microbiol 1986;24(3):357-363.
4. Belsheim MR, Darwish RZ, Watson WC, Schieven B. Bacterial L-form isolation from inflammatory bowel disease patients. Gastroenterology 1983;85(2):364-369.
5. Liu Y, Van Kruiningen HJ, West AB, Cartun RW, Cortot A, Colombel JF. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 1995;108(5):1396-1404.
6. Wakefield AJ, Pittilo RM, Sim R, Cosby SL, Stephenson JR, Dhillon AP, et al. Evidence of persistent measles virus infection in Crohn's disease. J Med Virol 1993;39(4):345-353.
7. Marks DJ, Mitchison NA, Segal AW, Sieper J. Can unresolved infection precipitate autoimmune disease? Curr Top Microbiol Immunol 2006;305:105-125.
8. Roche JK, Fiocchi C, Youngman K. Sensitization to epithelial antigens in chronic mucosal inflammatory disease. Characterization of human intestinal mucosa-derived mononuclear cells reactive with purified epithelial cell-associated components in vitro. J Clin Invest 1985;75(2):522- 530.
9. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2006;52(2):171-181.
10. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-549.
11. Winslet MC, Allan A, Poxon V, Youngs D, Keighley MR. Fecal diversion for Crohn's colitis: a model to study the role of the fecal stream in the inflammatory process. Gut 1994;35(2):236-242.
12. Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, et al. Effect of fecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;338(8770):771-774.
13. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114(2):262-267.
14. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualized ileal ulcers preceding symptoms. Gut 1992;33(3):331-335.
15. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126(6):1620-1633.
16. O'Morain C, Segal AW, Levi AJ. Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. Br Med J 1984;288(6434) :1859-1862.
17. Saverymuttu S, Hodgson HJ, Chadwick VS. Controlled trial comparing prednisolone with an elemental diet plus non-absorbable antibiotics in active Crohn's disease. Gut 1985;26(10):994-998.
18. Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 2006;367(9518) :1271-1284.
19. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411(6837):599-603.
20. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411(6837):603-606.
21. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357(9272):1925-1928.
22. McGovern DP, Hysi P, Ahmad T, van Heel DA, Moffatt MF, Carey A, et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet 2005;14(10):1245-1250.
23. Brand S, Staudinger T, Schnitzler F, Pfennig S, Hofbauer K, Dambacher J, et al. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 2005;11(7):645- 652.
24. Peltekova VD, Wintle RF, Rubin LA, Amos CI, Huang Q, Gu X, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004;36(5):471-475.
25. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314(5804):1461-1463.
26. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007;39:207-211.
27. Leong RW, Armuzzi A, Ahmad T, Wong ML, Tse P, Jewell DP, et al. NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population. Aliment Pharmacol Ther 2003;17(12):1465-1470.
28. Yamazaki K, Takazoe M, Tanaka T, Kazumori T, Nakamura Y. Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease. J Hum Genet 2002;47(9):469-472.
29. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002;122(4):867-874.
30. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB. J Biol Chem 2001;276(7):4812-4818.
31. Gutierrez O, Pipaon C, Inohara N, Fontalba A, Ogura Y, Prosper F, et al. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-κB activation. J Biol Chem 2002;277(44): 41701-41705.
32. Lala S, Ogura Y, Osborne C, Hor SY, Bromfield A, Davies S, et al. Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterology 2003;125(1):47-57.
33. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003;278(8):5509- 5512.
34. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003;278(11):8869-8872.
35. Kobe B, Deisenhofer J. Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease A. J. Mol Biol 1996;264:1028-1043.
36. Netea MG, Kullberg BJ, de Jong DJ, Franke B, Sprang T, Naber TH, et al. NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol 2004;34(7):2052- 2059.
37. Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004;5(8):800-808.
38. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Hafner R, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001;29(1):19-20.
39. Shnyra A, Brewington R, Alipio A, Amura C, Morrison DC. Reprogramming of lipopolysaccharide-primed macrophages is controlled by a counterbalanced production of IL-10 and IL-12. J Immunol 1998;160(8):3729-3736.
40. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307(5710):731-734.
41. Watanabe T, Kitani A, Murray PJ, Wakatsuki Y, Fuss IJ, Strober W. Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signalling and induction of antigen-specific colitis. Immunity 2006;25(3):473-485.
42. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal α-defensin expression. Gut 2004;53(11): 1658-1664.
43. Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, Lopez-Boado YS, Stratman JL, et al. Regulation of intestinal α-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999;286(5437):113-117.
44. Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, Kagnoff MF, et al. Nod2 mutation in Crohn's disease potentiates NF-κB activity and IL-1β processing. Science 2005;307(5710):734-738.
45. Ogura Y, Saab L, Chen FF, Benito A, Inohara N, Nunez G. Genetic variation and activity of mouse Nod2, a susceptibility gene for Crohn's disease. Genomics 2003;81(4):369-377.
46. Pauleau AL, Murray PJ. Role of nod2 in the response of macrophages to Toll-like receptor agonists. Mol Cell Biol 2003;23(21):7531-7539.
47. James DG. A clinicopathological classification of granulomatous disorders. Postgrad Med J 2000;76(898):457-465.
48. Thrasher AJ, Keep NH, Wientjes F, Segal AW. Chronic granulomatous disease. Biochim Biophys Acta 1994;1227(1-2):1-24.
49. Dieckgraefe BK, Korzenik JR, Husain A, Dieruf L. Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. Eur J Pediatr 2002;161(suppl 1):S88-92.
50. Segal AW, Loewi G. Neutrophil dysfunction in Crohn's disease. Lancet 1976;2(7979):219-221.
51. Morain CO, Segal AA, Walker D, Levi AJ. Abnormalities of neutrophil function do not cause the migration defect in Crohn's disease. Gut 1981;22(10):817-822.
52. Wandall JH, Binder V. Leukocyte function in Crohn's disease. Studies on mobilization using a quantitative skin window technique and on the function of circulating polymorphonuclear leukocytes in vitro. Gut 1982;23(3):173-180.
53. Rhodes JM, Potter BJ, Brown DJ, Jewell DP. Serum inhibitors of leukocyte Chemotaxis in Crohn's disease and ulcerative colitis. Gastroenterology 1982;82(6):1327-1334.
54. Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, Al-Lazikani B, et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006;367(9511):668-678.
55. Kishimoto T. Interleukin-6: from basic science to medicine - 40 years in immunology. Annu Rev Immunol 2005;23:1-21.
56. Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000;79(3):155-169.
57. Vavricka SR, Musch MW, Chang JE, Nakagawa Y, Phanvijhitsiri K, Waypa TS, et al. hPepT1 transports muramyl dipeptide, activating NF-κB and stimulating IL-8 secretion in human colonic Caco2/bbe cells. Gastroenterology 2004;127(5):1401-1409.
58. Hugot JP, Alberti C, Berrebi D, Bingen E, Cezard JP. Crohn's disease: the cold chain hypothesis. Lancet 2003;362(9400):2012-2015.
59. Summers RW, Elliott DE, Urban JF Jr, Thompson R, Weinstock JV. Trichuris suis therapy in Crohn's disease. Gut 2005;54(1):87-90.
60. Sutherland LR, Ramcharan S, Bryant H, Fick G. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990;98(5, pt 1):1123-1128.
61. Sher ME, Bank S, Greenberg R, Sardinha TC, Weissman S, Bailey B, et al. The influence of cigarette smoking on cytokine levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 1999;5(2):73-78.
62. Emmanuel AV, Kamm MA. Laser Doppler measurement of rectal mucosal blood flow. Gut 1999;45(1):64-69.
63. Issekutz AC. Vascular responses during acute neutrophilic inflammation. Their relationship to in vivo neutrophil emigration. Lab Invest 1981;45(5):435-441.
64. Brandt E, Colombel JF, Ectors N, Gambiez L, Emilie D, Geboes K, et al. Enhanced production of IL-8 in chronic but not in early ileal lesions of Crohn's disease (CD). Clin Exp Immunol 2000;122(2):180-185.
65. Ryan P, Kelly RG, Lee G, Collins JK, O'Sullivan GC, O'Connell J, et al. Bacterial DNA within granulomas of patients with Crohn's disease - detection by laser capture microdissection and PCR. Am J Gastroenterol 2004;99(8):1539-1543.
66. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003;361(9363):1111-1118.
67. Korzenik JR, Podolsky DK. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 2006;5(3):197-209.
68. Rutgeerts PJ. Review article: the limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 2001;15(10):1515-1525.
69. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ. Sargramostim for active Crohn's disease. N Engl J Med 2005;352(21):2193-2201.
70. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003;21(7):785-789.